pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$GSKGSK plc

$GSK52.43+0.90%
London, GBupdated 27m ago

GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 8
  • company$GLAXFGSK plc6 co-mentions · 6 sources
  • tagInfectious Disease6 co-mentions · 6 sources
  • drugdolutegravir sodium2 co-mentions · 2 sources
  • drugcabotegravir LA2 co-mentions · 2 sources
  • drugcabotegravir sodium2 co-mentions · 2 sources
  • drugdolutegravir sodium ODT2 co-mentions · 2 sources
  • drugdostarlimab1 co-mentions · 1 sources
  • drugbepirovirsen sodium1 co-mentions · 1 sources
pipeline
15
marketed
2
phase 3
5
catalysts ytd
10
approvals ytd
0
recalls ytd
0

Pipeline(15)

view full pipeline →
pipeline depth15 products
Phase 1: 2Phase 2: 4Phase 3: 5Marketed: 2pre_registration: 2
2Phase 14Phase 25Phase 32Marketed2pre_registration
Marketed
depemokimab
Nasal Polyps (Nasal Polyposis)
Marketed
ibrexafungerp citrate
Aspergillosis
1,3-beta-glucan synthase
Phase 3
belimumab
Systemic Sclerosis (Scleroderma)
Tumor necrosis factor ligand superfamily member 13B
Phase 3
bepirovirsen sodium
Hepatitis B
Phase 3
camlipixant
Chronic Cough
P2X purinoceptor 3
Phase 3
meningococcal [serotype B] vaccine
Neisseria meningitidis Infections
Neisserial heparin binding antigen
Phase 3
velzatinib
Gastrointestinal Stromal Tumor (GIST)
Phase 2
GSK-101
Human Epidermal Growth Factor Receptor 2 Low Breast Cance…
Sodium channel protein type 9 subunit alpha
Phase 2
GSK-4382276A
Seasonal Influenza
Phase 2
GSK-5536522
Influenza A Virus, H5N1 Subtype Infections
Phase 2
dostarlimab
Rectal Cancer
Programmed cell death protein 1
Phase 1
CB-06036
Hepatitis B

📅 Upcoming

Oct 28, 2026
earnings
$GSK52.43+0.90%
in 2mo
GSK plc earnings
GSK plc
→

🕒 Recent(90d)

earnings (2)
Jul 29, 2026
earnings
$GSK52.43+0.90%
23d ago
GSK plc earnings
GSK plc
→
Jul 28, 2026
earnings
$GSK52.43+0.90%
24d ago
GSK plc earnings
GSK plc
→
view all catalysts →
🐶 Hiring Signal
next earnings Oct 28, 2026
706 open roles at GSK plc →

Where GSK plc is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaInfectious Disease & Vaccines 228Oncology 109Gastroenterology 41Respiratory 29Immunology & Inflammation 14Hematology 11
departmentBusiness Development & Sales 103Commercial 95Medical Affairs 67IT & Engineering 53Manufacturing / CMC 51Regulatory 36

News

no news has mentioned this company yet
identifiers
ticker
$GSK
SEC CIK
0001131399
country
GB
source
sec_tickers
top tags
Infectious Disease7Oncology4Colorectal Cancer2Immunology2NSCLC2
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed just now
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?